Shares of G1 Therapeutics Inc (NASDAQ:GTHX) reached a new 52-week high on Tuesday . The company traded as high as $39.85 and last traded at $40.15, with a volume of 205803 shares. The stock had previously closed at $37.55.
A number of research firms have recently weighed in on GTHX. BidaskClub upgraded shares of G1 Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, March 15th. Needham & Company LLC increased their target price on shares of G1 Therapeutics to $42.00 and gave the stock a “buy” rating in a report on Tuesday, March 13th. Cowen reissued a “buy” rating on shares of G1 Therapeutics in a research note on Monday, March 5th. BTIG Research reissued a “buy” rating and issued a $48.00 price target on shares of G1 Therapeutics in a research note on Wednesday, March 7th. Finally, JPMorgan Chase & Co. reissued an “overweight” rating and issued a $39.00 price target (up from $33.00) on shares of G1 Therapeutics in a research note on Tuesday, March 6th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. G1 Therapeutics currently has a consensus rating of “Buy” and an average target price of $38.20.
G1 Therapeutics (NASDAQ:GTHX) last released its quarterly earnings results on Wednesday, February 21st. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($0.02). equities analysts predict that G1 Therapeutics Inc will post -2.47 EPS for the current fiscal year.
In related news, insider Rajesh Malik sold 3,776 shares of the stock in a transaction dated Thursday, March 15th. The shares were sold at an average price of $38.18, for a total value of $144,167.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last three months, insiders sold 13,578 shares of company stock valued at $358,510.
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Franklin Resources Inc. increased its stake in shares of G1 Therapeutics by 10.1% during the fourth quarter. Franklin Resources Inc. now owns 1,535,616 shares of the company’s stock valued at $30,467,000 after purchasing an additional 141,000 shares in the last quarter. BlackRock Inc. increased its stake in shares of G1 Therapeutics by 113.5% during the fourth quarter. BlackRock Inc. now owns 745,445 shares of the company’s stock valued at $14,790,000 after purchasing an additional 396,215 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of G1 Therapeutics by 9.3% during the fourth quarter. Geode Capital Management LLC now owns 94,366 shares of the company’s stock valued at $1,872,000 after purchasing an additional 8,061 shares in the last quarter. Chartwell Investment Partners LLC increased its stake in shares of G1 Therapeutics by 5.0% during the third quarter. Chartwell Investment Partners LLC now owns 92,558 shares of the company’s stock valued at $2,303,000 after purchasing an additional 4,388 shares in the last quarter. Finally, Vanguard Group Inc. bought a new position in shares of G1 Therapeutics during the second quarter valued at approximately $1,291,000. 42.78% of the stock is owned by institutional investors and hedge funds.
WARNING: “G1 Therapeutics (GTHX) Hits New 1-Year High at $39.85” was reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/03/22/g1-therapeutics-gthx-hits-new-1-year-high-at-39-85.html.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.